Rudman Growth Hormone Study: What the 1990 Trial Showed

The Rudman growth hormone study did not show that human growth hormone makes people live longer or grow younger. Published on July 5, 1990, this 1990 New England Journal of Medicine report tracked 21 healthy older men for six months. Twelve men received human growth hormone (hGH), and nine received no treatment.

The treated men gained lean tissue and lost fat, sparking decades of anti-aging claims. Yet the trial never measured muscle strength, stamina, daily function, or lifespan. Knowing what it actually tested helps you separate sales pitches from medical evidence.

Inside the 1990 Rudman growth hormone study

Daniel Rudman and colleagues asked whether replacing growth hormone changes body composition in older men. They looked for men with low insulin-like growth factor I (IGF-I), a hormone the liver makes in response to growth hormone. Twenty-six healthy men aged 61 to 81 enrolled with IGF-I below 350 U/L and weight at 90% to 120% of age standards.

Five men left during a six-month baseline period, leaving 21 men for the six-month treatment phase. A computer randomly assigned 12 men to hGH and nine to no injections. As Mary Lee Vance noted in a 2003 New England Journal of Medicine perspective, the trial was not double-blind and used no placebo.

In the trial, treated men received about 0.03 mg/kg of biosynthetic hGH under the skin three times weekly, adjusted by monthly IGF-I labs. That schedule is a historical trial fact, not a dosing guide.

What the Rudman growth hormone study measured and found

Researchers measured body potassium to estimate lean and fat mass, four-site caliper skin thickness, and bone density at nine sites. The paper did not name a single primary endpoint. In the 12 treated men, lean mass rose 8.8%, adipose fat mass fell 14.4%, and lumbar spine density (vertebrae 1–4) rose 1.6%.

Skin thickness rose 7.1% in the hGH group, which missed statistical significance (P=0.07). Changes in the nine untreated men were also nonsignificant. For within-group fat loss, the paper's text printed P<0.005 while Table 4 printed P=0.05.

Comparing the two groups directly is the stricter test. Between groups, only lean mass differed significantly (P<0.018), while fat mass (P=0.13) and skin thickness (P=0.10) did not.

The paper reported no fluid swelling, local injection reactions, or heart-muscle thickening over six months. Still, treated systolic blood pressure rose from 119.1 to 127.2 mm Hg and fasting glucose rose from 5.4 to 5.8 mmol/L (both P<0.05). Rudman tested direct hGH, so its results cannot be transferred to sermorelin.

How "10 to 20 years of aging" gets misread

Gray-market pitches often claim this trial proved hGH turns back aging by 10 to 20 years. Rudman's discussion actually wrote that the six-month tissue shifts were "equivalent in magnitude to the changes incurred during 10 to 20 years of aging."

That sentence was an analogy about tissue numbers, not a biological clock. Potassium-based lean mass counts water and internal organs alongside muscle, and the trial never tested strength, endurance, or quality of life. Six months in 12 treated men cannot show that anyone lives longer.

What editorials and later trials showed

In a July 5, 1990 editorial beside Rudman's paper, Mary Lee Vance warned that the study was only a beginning. She wrote that "its general use now or in the immediate future is not justified."

In a 1993 Clinical Endocrinology study, Lester Cohn and colleagues enrolled 83 older men with low IGF-I. The report gives assignment counts of 62 men to hGH and 21 to untreated control, and separately reports 15 departures during baseline. Treatment was scheduled for months 7 to 18.

Twenty-seven hGH-group men and two controls left after month six, mostly for reasons judged probably unrelated to treatment. Among completers, treated men reached 106% of baseline lean mass and 84% of fat, versus 97% lean mass in controls.

Cohn's team also reported a "substantial frequency" of side effects potentially related to hGH. They counted 10 cases of carpal tunnel syndrome (wrist nerve compression), four of gynaecomastia (male breast enlargement), and three of high blood sugar. One man had both wrist and breast symptoms, and higher on-treatment IGF-I levels tracked with more reactions.

In 2002, Marc Blackman and colleagues published a 26-week randomized trial in JAMA of 57 women and 74 men aged 65 to 88. Four double-blind arms tested hGH with sex steroids (35), hGH alone (30), sex steroids alone (35), and double placebo (31). Lean mass rose 3.1 kg in men and 1.0 kg in women on hGH alone, versus 0.1 kg and 0.4 kg on placebo.

Yet hGH alone did not significantly improve muscle strength or treadmill stamina (peak oxygen uptake, or VO2max). Only men on combined therapy had marginal strength gains (13.5 kg, P=0.05) and higher VO2max. Fluid swelling hit 39% of women on hGH versus 0% on placebo, and joint pain hit 41% of men on hGH versus 0%.

Diabetes or glucose intolerance occurred in 18 men given hGH versus seven not given hGH (P=0.006). Carpal tunnel symptoms hit 32% of men on combined therapy versus 0% on placebo. Blackman's team concluded that "GH interventions in the elderly should be confined to controlled studies."

A 2007 Annals of Internal Medicine review by Hau Liu and colleagues pooled 31 articles covering 18 study populations. Across those trials, 220 GH-treated participants completed an average of 27 weeks. In 2003, Vance had already concluded that "Antiaging therapy with growth hormone has not yet been proved effective according to objective outcome criteria."

In Liu's 2007 review, lean mass rose 2.1 kg and fat fell 2.1 kg (both P<0.001), with unchanged weight (0.1 kg, P=0.87) and bone density. Swelling, joint pain, carpal tunnel, male breast enlargement, and glucose problems occurred more often. The authors wrote: "On the basis of this evidence, GH cannot be recommended as an antiaging therapy."

As of October 17, 2026, the day this article was written, that caution holds. A June 15, 2026 review in Growth Hormone & IGF Research found "no clinically significant improvements in health or well-being" in normal aging.

That review also noted that "Numerous adverse side effects have been well-documented" in older adults. Those direct-hGH findings do not establish benefits or risks for a CJC-1295/ipamorelin blend.

Law, regulation, and how sermorelin or CJC-1295/ipamorelin differ

Under 21 U.S.C. § 333(e), knowingly distributing hGH (somatrem, somatropin, or an analogue) is restricted to physician-ordered uses authorized by Health and Human Services. In FDA Import Alert 66-71, revised April 7, 2026, FDA states that anti-aging, bodybuilding, and athletic uses are not authorized. Biological hGH also cannot use 503A or 503B compounding exemptions; see are peptides legal in the US.

Unlike hGH, sermorelin, CJC-1295, and ipamorelin signal the pituitary to release your own growth hormone; see sermorelin versus HGH. A 2006 Neurobiology of Aging trial randomized 100 healthy adults aged 60 to 85, and 89 completed six months. Some cognitive tests favored sermorelin, without establishing daily-life benefit or longer life.

In a 2006 endocrine study of adults aged 21 to 61, long-acting CJC-1295 raised mean IGF-I 1.5- to 3-fold for 9 to 11 days. That trial tested the DAC form, not non-DAC CJC-1295 or an ipamorelin blend.

A 1999 Pharmaceutical Research study showed intravenous ipamorelin released growth hormone in healthy men. The PubMed search used for this article did not identify a human longevity trial of the CJC-1295/ipamorelin pair.

Raising IGF-1 still requires medical oversight; see IGF-1 levels by age and do peptides cause cancer. A November 2024 FDA briefing on CJC-1295 noted flushing, faster heart rate, low blood pressure, and site reactions.

FDA reviewers wrote that "Some of these AEs warrant further study" in clinical use. An August 2024 FDA ipamorelin memo reviewed an intravenous post-surgery study. It stated that "it is unclear whether the two deaths were related to ipamorelin."

A formerly marketed sermorelin product, Geref, has since been discontinued. Geref was approved December 28, 1990 and September 26, 1997, discontinued in 2008, and withdrawn June 18, 2009. A 2013 Federal Register notice confirmed the withdrawal was not for safety or effectiveness reasons.

Today's compounded sermorelin is different from an FDA-approved product: the formulation offered here is not FDA-approved. CJC-1295 and ipamorelin are not FDA-approved drugs, and their compounded blend is not FDA-approved. As the FDA's compounding guide states, compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.

How a provider evaluates growth-hormone peptides

For these compounded peptides, a licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. Sermorelin or CJC-1295/ipamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy, with a clinician setting the protocol and follow-up labs.